SCHEMBL4485740

SCHEMBL4485740

NC(=O)c1c(-c2ccc(N)cc2)c[nH]c1NC=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 1/20 0.35
DYRK1B Q9Y463 2/20 0.34
CLK1 P49759 1/20 0.34
DYRK1A Q13627 1/20 0.34
DYRK2 Q92630 1/20 0.34
CDK8 P49336 5/20 0.33
PIM1 P11309 3/20 0.33
KDR P35968 2/20 0.33
MAP3K11 Q16584 2/20 0.33
PIM3 Q86V86 2/20 0.33
PIM2 Q9P1W9 2/20 0.33
CDC7 O00311 2/20 0.33
ROCK2 O75116 2/20 0.33
MAP4K4 O95819 2/20 0.33
PRKACA P17612 2/20 0.33
CDK2 P24941 2/20 0.33
GSK3B P49841 2/20 0.33
HIPK2 Q9H2X6 2/20 0.33
CYP3A4 P08684 1/20 0.33
PLK4 O00444 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486233 0.80 PKM (0.37) CAMKK2DYRK1BCLK1DYRK1ADYRK2
SCHEMBL4475436 0.75 GSK3B (0.46) DYRK1BDYRK1ACDK8KDRCDC7
SCHEMBL4481644 0.75 KDR (0.43) CDK8KDRGSK3BCYP3A4ABL1
SCHEMBL10057754 0.72 NOTUM (0.39) MAPT
SCHEMBL4481101 0.70 ALDH1A1 (0.46) KDRCYP3A4HTTMAPTRAB9A
SCHEMBL4479411 0.65 MAP3K11 (0.48) DYRK1BCLK1DYRK1ADYRK2MAP3K11
SCHEMBL4482796 0.64 KDR (0.53) KDRRAB9A
SCHEMBL4490967 0.64 NPC1 (0.54) DYRK1AKDRROCK2PRKACACDK2
SCHEMBL22086338 0.64 HTT (0.47) CAMKK2DYRK1ACDK8PIM1KDR
SCHEMBL20898163 0.64 HTT (0.47) CAMKK2DYRK1ACDK8PIM1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US disclosed
EP-1851198-B1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA SA (FR) 2008-12-31 EP disclosed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US disclosed
EP-1851198-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2007-11-07 EP disclosed
WO-2006084996-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof PRMT1, ADPRS, RRM2B CAMKK2 4239/4885DYRK1B 1072/4885CLK1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.